Filtered By:
Source: Heart Rhythm
Condition: Atrial Fibrillation

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 356 results found since Jan 2013.

Irregularity and lack of p-waves in short tachycardia episodes predict atrial fibrillation and ischemic stroke
Atrial fibrillation (AF) is defined as an irregular supraventricular tachycardia (SVT) without p-waves, with a duration>30s. It is not known whether AF characteristics in shorter SVT episodes predict AF and stroke.
Source: Heart Rhythm - February 12, 2018 Category: Cardiology Authors: Linda S.B. Johnson, Anders P. Persson, Per Wollmer, Steen Juul-M öller, Tord Juhlin, Gunnar Engström Source Type: research

Irregularity and lack of p waves in short tachycardia episodes predict atrial fibrillation and ischemic stroke
Atrial fibrillation (AF) is defined as an irregular supraventricular tachycardia (SVT) without p waves, with duration>30 seconds. Whether AF characteristics during short SVT episodes predict AF and stroke is not known.
Source: Heart Rhythm - February 12, 2018 Category: Cardiology Authors: Linda S.B. Johnson, Anders P. Persson, Per Wollmer, Steen Juul-M öller, Tord Juhlin, Gunnar Engström Source Type: research

Subclinical Atrial Fibrillation: The significance of progression to longer episodes
Subclinical atrial fibrillation (SCAF) is a term to describe short-lasting (minutes to hours), asymptomatic AF detected via long-term continuous monitoring, typically using an implanted pacemaker, defibrillator or cardiac monitor (1). Both the TRENDS and ASSERT studies have shown that SCAF is associated with an increased risk of stroke (1, 2). However, unlike clinical AF where stroke risk is increased 4-5 times, the risk is only 2-2.5 times increased, and the absolute risk of stroke observed in these studies was much lower than expected based on the subjects ’ CHADS-2 score (1-3).
Source: Heart Rhythm - December 1, 2017 Category: Cardiology Authors: Jeff S. Healey, Jorge A. Wong Source Type: research

Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients treated with vitamin K antagonists: A review
Identifying patients who are likely to achieve and maintain a therapeutic INR when prescribed a vitamin K antagonist (VKA) for stroke prevention in atrial fibrillation (AF) and venous thromboembolism (VTE) is challenging. The SAMe-TT2R2 score was developed based on common clinical factors that can highlight patients who may be unable to achieve and maintain good anticoagulation control and for whom a ‘trial of warfarin’ would be inadvisable. This review summarises the main published prospective and retrospective studies that have validated the SAMe-TT2R2 score in AF and VTE patients treated with a VKA and how the SAMe-...
Source: Heart Rhythm - November 24, 2017 Category: Cardiology Authors: Hanis Zulkifly, Gregory Y.H. Lip, Deirdre A. Lane Source Type: research

Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review
Identifying patients who are likely to achieve and maintain a therapeutic international normalized ratio when prescribed a vitamin K antagonist for stroke prevention in atrial fibrillation (AF) and venous thromboembolism (VTE) is challenging. The SAMe-TT2R2 score was developed on the basis of common clinical factors that can highlight patients who may be unable to achieve and maintain good anticoagulation control and for whom a “trial of warfarin” would be inadvisable. This review summarizes the main published prospective and retrospective studies that have validated the SAMe-TT2R2 score in patients with AF and VTE tre...
Source: Heart Rhythm - November 24, 2017 Category: Cardiology Authors: Hanis Zulkifly, Gregory Y.H. Lip, Deirdre A. Lane Tags: Contemporary Review Source Type: research

Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden
In patients with cardiac implanted electronic devices (CIEDs) detection of new atrial fibrillation (AF) is associated with an increased risk of stroke.
Source: Heart Rhythm - November 6, 2017 Category: Cardiology Authors: Giuseppe Boriani, Taya V. Glotzer, Paul D. Ziegler, Mirko De Melis, Lorenza Mangoni di S. Stefano, Milan Sepsi, Maurizio Landolina, Maurizio Lunati, Thorsten Lewalter, A. John Camm Source Type: research

Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: comparison between uninterrupted direct oral anticoagulants and warfarin administration
The effect of uninterrupted oral anticoagulant use in patients with chronic kidney disease (CKD) during catheter ablation for atrial fibrillation (AF) is not fully understood.
Source: Heart Rhythm - October 26, 2017 Category: Cardiology Authors: Satoshi Yanagisawa, Yasuya Inden, Aya Fujii, Monami Ando, Junya Funabiki, Yosuke Murase, Masaki Takenaka, Noriaki Otake, Yoshihiro Ikai, Yusuke Sakamoto, Rei Shibata, Toyoaki Murohara Source Type: research

Atrial Fibrillation and Cognitive Decline —Another Piece for a Big Puzzle
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its prevalence is increasing over time.1, 2 AF is associated with an increased risk of stroke,3 heart failure,4 and death.5-7 In recent years, evidence has emerged to indicate that AF is associated with another growing public health problem: cognitive impairment and dementia.8 Although the evidence is compelling, existing studies suffer from several limitations such as reliance on the Mini-Mental State Examination, cross-sectional design, and lack of attention to domain-specific changes.
Source: Heart Rhythm - October 10, 2017 Category: Cardiology Authors: Lin Y. Chen, Win-Kuang Shen Source Type: research

Percutaneous Left Atrial Appendage Closure is Not Ready for Routine Clinical Use
Both Watchman and NOACs are treatment strategies designed to prevent stroke in patients with atrial fibrillation (AF). For practical reasons device trials cannot enroll as many patients as drug trials, however, a comparison of the Watchman and NOAC trials serves to highlight the challenge of predicting efficacy of a treatment when event rates are low. Four large noninferiority trials compared NOAC to warfarin therapy for stroke prevention in patients with AF. 1-4 We will focus on the RELY and ARISTOTLE trials because they enrolled patients with similar stroke-risk (age, CHADS2 score, etc.) to those in the Watchman trials.
Source: Heart Rhythm - October 10, 2017 Category: Cardiology Authors: John Mandrola, Andrew Foy, Gerald Naccarelli Source Type: research

Left Atrial Appendage Closure Devices: A Reasonable Therapeutic Alternative
Preventing stroke is arguably the most important goal in the management of atrial fibrillation (AF). For decades, oral anticoagulation (OAC) has been the therapeutic mainstay for stroke prophylaxis – initially warfarin, and more recently, non-warfarin oral anticoagulants (NOACs). However, many patients are poor candidates for lifelong OAC therapy. This clinical need prompted the emergence of the therapeutic alternative, left atrial appendage closure (LAAC). Herein, I discuss the clinical evi dence supporting LAAC’s role as a reasonable stroke prevention alternative.
Source: Heart Rhythm - October 10, 2017 Category: Cardiology Authors: Vivek Y. Reddy Source Type: research

Atrial fibrillation and cognitive decline: Another piece for a big puzzle
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its prevalence is increasing over time.1,2 AF is associated with an increased risk of stroke,3 heart failure,4 and death.5 –7 In recent years, evidence has emerged to indicate that AF is associated with another growing public health problem: cognitive impairment and dementia.8 Although the evidence is compelling, existing studies suffer from several limitations, such as reliance on the Mini-Mental State Examination, c ross-sectional design, and lack of attention to domain-specific changes.
Source: Heart Rhythm - October 10, 2017 Category: Cardiology Authors: Lin Y. Chen, Win-Kuang Shen Tags: Editorial Commentary Source Type: research

Utility and Limitations of Long-Term Monitoring of Atrial Fibrillation Using an Implantable Loop Recorder
Atrial fibrillation (AF) is the most common cardiac arrhythmia diagnosed and treated in the world. The treatment of patients ’ symptoms as well as the prevention of stroke and heart failure is dependent on accurate detection and characterization of AF. A variety of electrocardiographic (ECG) monitoring techniques are being used for these purposes. However, these intermittent ECG monitoring techniques have been shown to under diagnose AF events, while having limited ability to characterize AF burden and density.
Source: Heart Rhythm - September 13, 2017 Category: Cardiology Authors: Randall Lee, Suneet Mittal Source Type: research

EP News: Basic and Translational
Atrial fibrillation affects more than 33 million people worldwide and increases the risk of stroke, heart failure, and death. Fourteen genetic loci have been associated with atrial fibrillation in European and Asian ancestry groups. To further define the genetic basis of atrial fibrillation, Christophersen et  al (Nat Genet 2017;49:946, PMID 28416818) performed large-scale, transancestry meta-analyses of common and rare variant association studies. The genome-wide association studies included 17,931 individuals with atrial fibrillation and 115,142 referents; the exome-wide association studies and rare v ariant association...
Source: Heart Rhythm - August 23, 2017 Category: Cardiology Authors: Penelope A. Boyden Tags: EP News: Basic and Translational Source Type: research

EWOLUTION – The Next Evolution in Appendage Closure?
Oral anticoagulation (OAC) is a class I indication for patients with non-valvular atrial fibrillation (AF) and 2 or more risk factors for stroke.1 However, many patients with AF are ineligible for OAC due to prohibitive bleeding. Subsequently, as a result of the pivotal role of the left atrial appendage (LAA) in the formation of thrombi, an alternative strategy to OAC is occlusion of the LAA.2 The WATCHMAN device (Boston Scientific Corporation, Marlborough, Massachusetts) is the only FDA approved LAA occlusion product studied in the randomized control trials (RCT) (Table 1).
Source: Heart Rhythm - June 22, 2017 Category: Cardiology Authors: Muhammad R. Afzal, Emile G. Daoud Source Type: research